Thanks, Scott, everyone. morning, good and
geography, the performance Our the base strong of business highlights well-diversified our predictability and from like as never which our point-of-view. further portfolio this quarter a momentum reinforces is as of well business, before
the The model That enabling position product growth. business underlying any of market. performance well one relied strength is for bringing Phase any has one of quarters our to our last company that of or business X on the demonstrates access XX never us
another continued new million this track product of and of revenue. again, on we feature on performance our key deliver year, is for expectation $XXX to of product plan revenue our Our new approximately remain
commercial which excludes the provide on rates making currency foreign impact segment highlights I plan supports operational an basis, that I versus negative As the our quarter, guidance. will comparisons certain the for financial of the be
divestiture-adjusted on will defined addition, be XXXX operational our comparisons to I In in earnings making our as a basis QX certain results lease.
the execution. grew basis to We the due performance power time This product to of well-thought-out strong strategy, and on various across quarter as platform, an achieving consistent total Viatris growth our top-line a portfolios. this operational believe and net first geographies flex for our X.X% sales
me highlights. Let commercial our into segment get
drove quarter. markets other quarter. in where business ahead of delivering sales momentum well-balanced expectations, two Italy, the year-over-year brands operational X% on the strong growth another developed our quarter makeup of basis. as strong approximately as UK, XX% of Europe net Spain, performed and an for several delivered Our markets, our well
Europe performance another in factor. of generics contributing was solid As
performed year-over-year expected flat expectations. than operational Wixela, ahead of a on delivered was and better business America Generics basis led North lenalidomide, and an by Our performance, also Xulane.
and strong supported XX% was Yupelri, business in market, year which year. brand Our last the grew this epinephrine by over demand
well nebulized market its a way in long-acting about number-one product Yupelri, which to to the nebulized growth in in this muscarinic become broader agent is market XX% is share long-acting continues the only and available and space. market, significant show on the enjoys the COPD
Symbicort. Our of introduction Breyna, America we about and our our in are North recent new on generic are launches excited track, very
We expect first-to-file if to eligible issue, days that is FDA's approval. when exclusivity the filer generic launch for future will final subject another which becomes be and determination ANDA XXX of this
the and our second and year, believe half poised confident market the growth North to both For America expectations Europe. the developed remain of we exceed of year-over-year we segment meet is or for full-year
expected Asia operational to Emerging growth, delivered versus strong-performing grow than full the by year. brands expected the with markets of the we full had year in geographies. Lipitor, than Emerging XX% our We expectations Middle strong East line like genetics quarter to year-over-year another were Celebrex. performance for led Lyrica, and remain and stronger the and year. and JANZ segment continuing confident meet for this for and our anticipate prior deliver performed better expectations and
retail-driven in on X% and meet quarter, growth the to year. other expectations We In Greater remain delivered due China, primarily in track to this we Viagra products China. operational our planned for
to Our evolving has our and focused while private on channel the ground. in on continuing team China presence expand in the the policy been navigating dynamics managing
received expanding very China. NDAs pipeline Dymista new building for our in approval We Formed from that products To and on of quarter. focused for SFDA this end, have in and also been our
this, was for to are accepted, products partner's eight our while review. Tyrvaya also under other NDA In addition active
as continued its second progress part of in Tyrvaya’s as launched Moving to to Viatris. Care. quarter Eye planned
our was focused value of drive optimized script direct-to-consumer During highest date. bridge brand's total continued Medicare remain including Furthermore, the to and in growth Tyrvaya's quarter, we first and TRX near for together, which increased share quarter, quarterly and the its maximizing support expectations the launched program prescriptions, prescriptions, for the campaign potential, provides launching per longer-term to achieved the fourth driving in we brand. on believe increasing
excited eye which care the addressing at range our of continued We progress pipeline, vision-related is of by are aimed disorders. a also
a of year. Our review PDUFA is MR-XXX reversal the of XX NDA active review of of under mydriasis program date this September for with
trial year. We on patient year. this completed MR-XXX enrollment QX this X Phase the later top-line trial data of first the have remain for in of and we of pivotal And second Phase treatment initiate X to expect track presbyopia the in
patient We have treatment MR-XXX enrollment Eye the expect Disease the and study, first X of Dry top-line XXXX. in in initiated Phase for data
treatment Phase MR-XXX on MR-XXX track. for for of and Vision the remain also a later Keratopathy initiating Disturbances blepharitis Neurotrophic this X Night program year. are MR-XXX for We of
GA other to pipeline beginning The FDA recently PDUFA Switching around date accepted XXXX. updates, Depot. and has submitted for news review our today of X, we with assigned announced the a March and NDA
Depot through GA backed X and believe Our greater experience fewer increased tolerability, patient and by and could we application is improve safety efficacy compliance. data, Phase injections,
confident XXXX. second to feeling of very the program that launch we in clinical continue believe the We Depot and our of GA half strength remain on track to in are
this to this bring also which are excited to year. equally opportunity in expect -- to about later patients we Europe, potential the our We for file
validation Our substance drug well product IND to program development, from of and of progressing track our as the end this remain drug by Botox year. file perspective. on biosimilar is the We as characterization, well
Our enrolled. with in track nearly XX,XXX XXX Low USA planned on Phase Xulane of X study Dose remains forward the program women the
targeting well targeting half XXXX. And we enrollment Effexor We Phase of on-schedule, our Generalized completion are by and first Japan X March of an in the filing are in is NDA Disorder Anxiety study for XXXX.
injectable as moving our all ahead complex Lastly, planned. programs are
Sanjeev? quarter call our Before to strong want another Sanjeev, I With performance. to the that, thank I for turn colleagues consistent and
